Clinical SuccessAMIX announced positive preliminary results from the first 15 patients of its proof-of-concept trial, showing significant and sustained pain reduction.
Market OpportunityThe potential to expand the addressable market beyond pancreatic cancer pain to other visceral cancers and earlier-stage pancreatic cancers could significantly enhance market opportunities.
Regulatory ProgressAMIX is on track regarding the regulatory timeline for its microchip-based platform technology, with a combined sensing and ablation early feasibility study expected to begin followed by a US pivotal trial.